Seer Highlights 62% Installed Base Growth, $23B TAM and $50M Buyback Plan
SEER•Seer filed its investor presentation ahead of the July 28 meeting, highlighting 62% installed base CAGR, 36% lower cash burn since 2022, a $23B proteomics TAM by 2034, annual SG&A and R&D cost cuts, and 84 peer-reviewed publications. Directors own 17%, authorized $50M buybacks with $25.5M left, hold $220M cash.
1. Investor Presentation Highlights
Seer presented its strategy for AI-driven proteomics, citing a $23 billion total addressable market by 2034, strategic collaborations in population-scale studies, and a next-generation detector in its innovation pipeline poised to expand the proteomics end market beyond mass spectrometry users.
2. Operational and Financial Performance
The company reported a 62 percent CAGR in installed base since 2021, a 36 percent reduction in annual cash burn since 2022, annual SG&A and R&D cost cuts, 84 peer-reviewed publications since 2022, over 235 patent filings, a cash position of $220 million, and an authorized $50 million share repurchase program with $25.5 million remaining.
3. Board Composition and Proxy Campaign
Seer’s board comprises five independent directors, averaging 5.5 year tenure, collectively holding 17 percent of shares, and has urged stockholders to support its seven nominees on the blue proxy card to counter activist Brent Radoff and Michael Torok, whom it argues lack relevant expertise and actionable value-creation plans.
